From the Journals

High parathyroid hormone level a marker for NAFLD and possibly NASH


 

FROM DIABETES & METABOLIC SYNDROME: RESEARCH & REVIEWS

TOPLINE:

A high parathyroid hormone (PTH) level was significantly associated with nonalcoholic fatty liver disease (NAFLD) and nonsignificantly associated with nonalcoholic steatohepatitis (NASH) in a meta-analysis.

METHODOLOGY:

  • The researchers conducted a systematic review and meta-analysis of 12 case-control studies of patients with NAFLD/NASH and a comparison group without NAFLD/NASH.
  • All studies had data on mean PTH levels in cases and controls.
  • Pooled weighted mean difference (WMD) was calculated by combining WMDs of each study using a random-effects model.

TAKEAWAY:

  • A meta-analysis of 10 studies with 1,051 patients with NAFLD and 1,510 controls revealed a significant association between high PTH level and NAFLD, with a pooled WMD of 5.479.
  • A meta-analysis of four studies with 99 patients with NASH and 143 controls revealed a trend toward an association of high PTH level and NASH, with a pooled WMD of 11.995; statistical significance was not achieved owing to inadequate power.
  • Both meta-analyses had high statistical heterogeneity (I2 of 82.4% for NAFLD and 81.0% for NASH).

IN PRACTICE:

“These findings may have clinical implications as they may suggest that high PTH level could be another biochemical marker of presence of NAFLD and possibly NASH,” the researchers wrote.

SOURCE:

This study was led by Aunchalee Jaroenlapnopparat, MD, Mount Auburn Hospital/Beth Israel Lahey Health, Cambridge, Mass. It was published online in Diabetes & Metabolic Syndrome: Research & Reviews. The study had no funding.

LIMITATIONS:

This systematic review and meta-analysis included observational studies, which might not show a causal relationship owing to potential confounding effects. Both meta-analyses demonstrated high statistical heterogeneity, probably because of differences in study design, population, and quality among the included studies. The number of studies and participants in the NASH-related analysis were limited, which may have compromised the statistical power of the analysis.

DISCLOSURES:

The authors have no relevant conflicts of interest.

A version of this article first appeared on Medscape.com.

Recommended Reading

Affording the cost of new obesity drugs? We can’t afford not to
MDedge Endocrinology
Intermittent fasting vs. calorie counting for weight loss
MDedge Endocrinology
Tirzepatide powers weight loss in two more pivotal trials
MDedge Endocrinology
Poor weight loss after bariatric surgery? Liraglutide may help
MDedge Endocrinology
Exercise program boosted physical, but not mental, health in young children with overweight
MDedge Endocrinology
Continuous glucose monitoring might help in managing postoperative hypoglycemia
MDedge Endocrinology
Benefits of bariatric surgery persist for 12 years
MDedge Endocrinology
Nonalcohol substance use disorder tied to bariatric surgery
MDedge Endocrinology
Obesity: Don’t separate mental health from physical health
MDedge Endocrinology
Using Ozempic for ‘minor’ weight loss: Fair or foul?
MDedge Endocrinology